Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

#160; "We are pleased to have advanced our microRNA therapeutic pipeline by presenting key data at scientific meetings, preparing to enter the clinic with RG-101 and working towards the nomination of a second microRNA candidate for clinical development."

Recent Corporate Highlights

  • Presented Positive Preclinical Data on RG-101, a GalNAc-conjugated anti-miR Targeting miR-122 for the Treatment of HCV, in Late-Breaking Poster at AASLD Meeting. At the 64th Annual American Association for the Study of Liver Diseases (AASLD) meeting, Regulus presented positive data from completed preclinical studies evaluating RG-101 for in vitro and in vivo potency, pharmacokinetic/pharmacodynamics, toxicology and safety pharmacology and inhibition of HCV replication. Pharmacologic potency of RG-101 was significantly enhanced by approximately 20 fold in vivo in both mice and non-human primates, relative to the unconjugated oligonucleotide of RG-101. RG-101 is rapidly taken up in the liver and metabolized to the active oligonucleotide, which has an approximately 14 day tissue half-life. In addition to the potency studies, Regulus tested the efficacy of RG-101 to reduce HCV viral load titer in a human chimeric liver mouse model infected with HCV. Up to a 2 log reduction in HCV viral load titer was observed, which is similar to that observed for oral direct-acting antivirals as monotherapy in this mouse model. The duration of action observed for RG-101 supports the potential for a once-a-month dosing regimen. Additionally, RG-101 has demonstrated an excellent preclinical safety profile and is well tolerated to date. Regulus expects to file a regulatory application for this program in the near term and expects to commence clinical studies in man in early 2014.
  • Presented Positive Preclinical Data on microRNA-21 (miR-21) in Alport Syndrome at The American Society of Nephrology (ASN) Kidney Week Meeting; Program Subject to Exclusive
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
    2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
    4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
    9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    11. Regulus to Present at Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    (Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
    (Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
    Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
    (Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
    (Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
    (Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
    (Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
    (Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
    Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
    ... CLARA, Calif., Feb. 18 Align Technology, Inc. (Nasdaq: ... notified of a purported declaratory judgment action filed against the ... United States District Court for the Southern District of Texas. ... 2009, but has not been served with a copy of ...
    ... supported entry into Company,s current Phase, ... 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that The Journal of Urology has published ... results for the Company,s proprietary Mycobacterial Cell Wall ...
    ... a world-leading provider of Hosted Microsoft Exchange, presents competitive risk-proof, out-of-the-box ... ... February 18, 2009 -- SherWeb , a global leader in ... Reseller Program last week. The newly implemented program provides IT ...
    ... Change" Campaign Part of International Effort to Combat Rare Diseases That Collectively ... ... CA (PRWEB) February 18, 2009 -- Students at Albany High School in ... some change to help support the first annual World Rare Disease Day, ...
    ... Red Wine & More , ... Mount Kisco, NY (PRWEB) February 18, ... resveratrol . It,s been shown to increase the life spans of yeast, ... School and the National Institute on Aging created a stir when they ...
    ... Regardless of where they are born in ... for many life-threatening disorders, a remarkable public health advance of ... today by the March of Dimes.All 50 states and the ... for 21 or more of the 29 serious genetic ...
    Cached Medicine News:Health News:Align Technology Asserts ClearCorrect Complaint Is Without Merit 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4Health News:SherWeb Launches Unique White Label Exchange Reseller Program 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 3Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 2Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 2Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 4
    ... FT is an affordable full-field, autoperimeter that includes ... least 40%. It has a small footprint and ... and easy two-button operation making it not only ... FT is the workhorse of the Paradigm family ...
    ... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
    ... Gentamycin sulfate is effective against gram positive ... mycoplasma, by interfering with bacterial protein synthesis ... ribosomes. Its suggested working concentration of 50 ... mammalian cells, thereby making a gentler alternative ...
    ... approach to practice management, built to address the ... market. OPIE was created by practicing O&P professionals ... this field, so it thinks the way you ... anything else available. If you believe there is ...
    Medicine Products: